Abstract: Background: Since early 90', growing body of evidence indicates that the Mediterranean diet with mild to moderate consumption of wine, mostly red wine, has a protective effect on cardiovascular diseases. Several mechanisms have been discussed to participate in the benefi cial effect of red wine, such as antioxidant or vasodilating activity. However, later it has been shown that also other alcoholic beverages have a protective effect on atherosclerosis. Up to now, data from the prospective, long-term, head-to-head comparisons of the effects of different drinks on markers of atherosclerosis are insuffi cient. Methods: The IVV (in vino veritas) study is a long-term, prospective, multicenter, randomized trial comparing the effect of red and white wines on the markers of atherosclerosis. One hundred and twenty healthy subjects with mild to moderate risk of atherosclerosis will be randomized to regular consumption of red wine (Pinot Noir) or white wine (Chardonnay-Pinot) for one year. The primary endpoint is the level of HDL-cholesterol at one year, while secondary endpoints are levels of other markers of atherosclerosis (LDL-cholesterol, C-reactive protein, myeloperoxidase, advanced oxidation protein product, interleukins 6 and 18, matrix metalloproteinases, glutathione s-transferase, monocyte chemoattractant protein 1, soluble CD40L).
The observation of so-called "French paradox" by Renaud and Lorgeril in 1992 (1) started an enormous effort to discover the mechanisms of the benefi cial effect of wine drinking on cardiovascular prognosis. Since early 90´ a number of experimental studies have been published, describing the protective effect of red wine on different pathways of the pathogenesis of atherosclerosis. Antioxidants fl avonoids and polyphenols became the fi rst substances contained in red wine with proven benefi cial effect in various diseases, such as inhibition of LDL oxidation or attenuation of ischemia-reperfusion injury (2) . However, several experimental studies have also shown that alcohol itself may have a protective impact (2) and these observations were confi rmed by the data from large population-based studies and registries, showing cardiovascular benefi ts of alcohol drinking, regardless of type of beverage while similar benefi ts were shown for red and white wines, beer and even liquors (3, 4) .
It has been shown in animal experiments and in vitro studies that there are major differences in basic characteristics between red and white wines. Red wine exhibits higher antioxidant capacity and protective effect against LDL-oxidation as compared with white wine (5-7). Rosenkranz et al (8) and Sparwel et al (9) have shown attenuation of platelet-derived growth factor receptor (PDGFR) signaling (an important pathogenic mechanism in the development of atherosclerosis) in rat and human vascular smooth muscle cells (VSMCs) induced by red wine, whereas white wine had no effect. On the other hand, Munday et al (10) did not fi nd any differences between red and white wine in serum lipoprotein profi le and fatty streak formation in C57BL/6 mouse atherosclerosis model. López et al. (11) observed a similar reduction in superoxide production and an increase in expression and activity of NO-synthase (iNOS) by dealcoholized red and white wines in a rat model while up-regulation of cyclo-oxygenase-2 (COX-2) was detected only in the red wine group. Moreover, Auger et al (12) described that both red wine and polyphenols-enriched white wine prevent early atherosclerosis in hamsters.
Regarding the effect on atherosclerosis, there is only limited evidence from the prospective head-to-head comparisons of different alcohol beverages in human subjects; the published studies were focused mostly on acute effect of drinking. Tousoulis et al (13) observed reactive hyperemia after beer and red wine con-sumption that was not detected after white wine, whiskey or water in healthy young individuals. Reduction in urinary prostaglandin PGF2α-III as a marker of oxidative stress was more expressed after red wine than after white wine in a study on healthy subjects by Pignatelli et al (14) . Pace-Asciak et al (15) did not fi nd any advantage in red wine over white wine in preventing platelet aggregation in healthy males. Similar increase in total antioxidant capacity as a result of red or white wine consumption was described by Pinzani et al (16) . Williams et al (17) did not observe any signifi cant difference in acute effect of red and white wine drinking on blood pressure, heart rate, plasma lipids, levels of interleukin-6 (IL-6), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in males with angiographic evidence of coronary artery disease (CAD). Moreover, comparable acute improvement of endothelial function after red and white wine drinking was reported by Whelan et al (18) in subjects with proven CAD. Blann et al (19) described increase in beta-thromboglobulin level after red wine whereas white wine had no effect. Until now, the longest exposition to red and white wines in a prospective trial was examined by Saranella et al (20) in their four-week study; they found in a group of thirty-six healthy females stronger anti-infl ammatory effect of the red wine as compared with white wine consumption.
Hitherto, prospective data from the long-term, head-to-head comparisons of the effects of red and white wines on markers of atherosclerosis are missing (21) .
Methods

Objective
The objective of the IVV trial is to compare the long-term effect of regular red and white wine drinking on the biomarkers of atherosclerosis.
Study overview
This is a prospective, multicenter, randomized, comparative study in one hundred and twenty individuals with mild to moderate risk of cardiovascular disease. Study protocol, information for patient, and informed consent are reviewed and approved by multicenter ethics committee as well as by local ethics committees in each institution before study initiation. Eligible individuals will be randomized to one regular drinking of either red wine (Pinot Noir, 2008, Moravia, Czech Republic) or white wine (Chardonnay-Pinot, 2008, Moravia, Czech Republic): women with body weight less than 70 kg 0.2 liter per day, women over 70 kg and men 0.3 liter per day; chemical specifi cations of the respective wines are shown in Table 1 . Participants will be followed on the intentionto-treat basis. Primary endpoint is the level of HDL-cholesterol, secondary endpoints are levels of other markers associated with progression of atherosclerosis (total-and LDL-cholesterol, triglycerides, oxidized LDL, C-reactive protein, advanced oxidation protein product, myeloperoxidase, interleukin 6, interleukin 18, matrix metalloproteinases, glutathione s-transferase, monocyte chemoattractant protein 1, soluble CD40L, fatty acid binding protein).
Population
One hundred and twenty asymptomatic individuals with mild to moderate risk of cardiovascular disease according to the HeartScore® (20) and without known acute or chronic infl ammatory disease and liver or renal disease will be eligible for this study.
Follow-up
Eligible individuals willing to participate in the IVV study will be (after the signing of informed consent) randomized into one of the two arms. Red or white wine will be supplied in bottles directly to participants' home in the respective amount. Each participant also obtains a workbook with instruction to make notes about daily consumption of the study wine as well as other alcohol beverages. Blood samples for the measurement of laboratory endpoint and safety parameters will be obtained at a random visit and then at one, six, and twelve months. All visits include physical examination and assessment of cardiovascular events and other medical history since the last visit. At twelve months, after the fi nal visit, the wine supply will be stopped.
During the study period no specifi c restrictions and recommendation are made with respect to diet, life-style or possible diagnostic or therapeutic procedures.
Safety assessment
Liver enzymes (alanine aminotransferase, aspartate aminotransferase, gamma glutamyltransferase, alkaline phosphatase) will be investigated at all visits. If any of the parameters exceed threefold (>3x) the upper limit of normal range (ULN), unscheduled safety visit will be performed in 7 to 14 days if any of the liver enzymes remains to be >3x ULN, wine consumption will be stopped.
Sample size calculation
Based on the data from short-term studies we expect a 13 % increase in HDL-cholesterol in the red wine-group and a 5 % rise in the white wine-group. With α=0.05 and 80 % power, the sample size to detect the signifi cant difference in HDL-cholesterol was calculated as 51 participants per group. With the planned 60 participants per group the study will have an 86 % power to detect the signifi cant difference. The IVV trial is the fi rst study focusing on the long-term prospective comparison of the effect of red and white wine consumption on HDL-cholesterol and other markers of atherosclerosis. Results of the IVV trial may extend our understanding of the widely discussed "French paradox".
